Kraig Biocraft Laboratories, Inc. (KBLB) Form 424B3 — May 22, 2026
Kraig Biocraft Laboratories filed a prospectus supplement updating its shelf registration with its Q1 2026 10-Q, which reveals severe financial distress. The company reported zero revenue for the quarter and a net loss of $942,720, bringing its accumulated deficit to $57.7 million. The filing includes explicit going-concern language, stating that net losses and capital deficiencies raise substantial doubt about the company's ability to continue operations. Management acknowledges that cash resources are insufficient to meet business objectives without additional financing.
Key figures
- Revenue
- 0
- Total Debt
- 10783506
- Total Assets
- 3721832
- Cash Position
- 2890990
- Shares Outstanding
- 1113049449
- Ceo annual salary
- 533474
- Ceo accrued salary
- 4489979
- Gold bullion value
- 514667
- Accumulated deficit
- 57651792
- Sepa commitment amount
- 10000000
- Sepa capital raised ytd
- 4118654
- Working capital deficit
- 7666616
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.